Skip to content

Panbela Therapeutics, Inc.

CIK 0001029125

← back to feed
Revenue (TTM)
$1.18M
+39.3% YoY Q3 Nov 2024
Net Income (TTM)
−$29.27M
+27.7% YoY Q3 Nov 2024
EPS Diluted (TTM)
−$0.08
−188.2% YoY Q3 Nov 2024
Gross Margin
50.5%
Q3 Nov 2024
Operating Margin
-2,529.8%
Q3 Nov 2024
Net Margin
-2,481.5%
Q3 Nov 2024
Free Cash Flow (TTM)
−$25.6M
Q3 Nov 2024
Cash
$142K
Q3 Nov 2024
Total Debt
$3.44M
Q3 Nov 2024
Shares Outstanding
4.85M sh
Q3 Nov 2024

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings